NCT00000809
Withdrawn
Phase 1
A Phase I Trial of the Safety and Immunogenicity of MN rsgp120/HIV-1 With the Adjuvants QS-21 and Alum Compared to MN rsgp120/HIV-1 and QS-21 in Infants Born to HIV-Infected Women
Overview
- Phase
- Phase 1
- Intervention
- Not specified
- Conditions
- HIV Infections
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- Status
- Withdrawn
- Last Updated
- 4 years ago
Overview
Brief Summary
The purpose of this study is to test the safety and effectiveness of two different formulations of an HIV vaccine in infants born to HIV-infected women.
Investigators
Eligibility Criteria
Inclusion Criteria
- Not provided
Exclusion Criteria
- Not provided
Outcomes
Primary Outcomes
Not specified
Similar Trials
Completed
Phase 1
A Study on the Reactogenicity, Safety and Immune Response of a Targeted Immunotherapy Against HSV in Healthy Japanese Participants Aged 18-40 YearsHerpes SimplexNCT05989672GlaxoSmithKline50
Completed
Phase 1
Safety and Immunogenicity Dose-finding Study of Adjuvanted SCB-2020S Vaccine in AdultsCOVID-19NCT05228314Clover Biopharmaceuticals AUS Pty Ltd153
Unknown
Phase 1
Safety and Immunogenicity of the Inactivated Koçak-19 Inaktif Adjuvanlı COVID-19 Vaccine Compared to PlaceboCOVID-19 VaccineNCT04838080Kocak Farma38
Completed
Phase 2
Safety and Immunogenicity of 2 Formulations of an Intramuscular A/H5N1 Pandemic Influenza Vaccine in ChildrenInfluenzaOrthomyxoviridae InfectionsInfluenza A Virus InfectionNCT00491985Sanofi Pasteur, a Sanofi Company240
Completed
Phase 1
Evaluating the Safety and Immunogenicity of Polyvalent DNA/gp120 HIV Vaccine in Healthy, HIV-uninfected AdultsHIV InfectionsNCT04927585Worcester HIV Vaccine42